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A B S T R A C T
In Positron Emission Tomography (PET) research, it is important to assess not only pharmacokinetics of a
radiotracer in vivo, but also of the drugs used in blocking/displacement PET studies. Typically, pharmacokinetic/
pharmacodynamic (PK/PD) analyses of drugs used in rodent PET studies are based on population average
pharmacokinetic profiles of the drugs due to limited blood volume withdrawal while simultaneously maintaining
physiological homeostasis. This likely results in bias of PET data quantification, including unknown bias of target
occupancy (TO) measurements. This study aimed to develop a High Performance Liquid Chromatography
(HPLC) method for PK/PD quantification of drugs used in preclinical rodent PET research, specifically the
translocator 18 kDa protein (TSPO) selective drug, PK11195, that used sub-millilitre blood volumes. The lowest
detection limit for the proposed HPLC method ranged between 7.5 and 10 ng/mL depending on the method used
to calculate the limit of detection, and the measured average relative standard deviation for intermediate pre-
cision was equal to 17.2%. Most importantly, we were able to demonstrate a significant difference between
calculated PK11195 concentrations at 0.5, 1, 2, 3, 5, 15 and 30min post-administration and individually
measured whole blood levels (significance level range from p < 0.05 to p < 0.001; one-way ANOVA, Dunnet's
post hoc test, p < 0.05). The HPLC method developed here uses sub-millilitre sample volumes to reproducibly
assess PK/PD of PK11195 in rodent blood. This study highlights the importance of individually measured PK/PD
drug concentrations when quantifying the TO from blocking/displacement rodent PET experiments.
1. Introduction
Positron Emission Tomography (PET) is a molecular imaging mod-
ality with numerous applications in both preclinical and clinical re-
search environment. This non-invasive technique offers great sensitivity
allowing for in vivo imaging of biochemical processes by injecting a
radioactive isotope-labelled compound at tracer levels (typically pico-
molar to micromolar range) [1]. One of the key applications of PET
imaging is to support target-occupancy (TO) studies with newly de-
veloped drugs, i.e. to serve as a companion biomarker. Furthermore, TO
studies can be pivotal at confirming selective target engagement of
novel PET radiotracers [2]. In human clinical trials, the percentage TO
quantification is supported by pharmacokinetic/pharmacodynamic
(PK/PD) analysis of arterial or venous blood for each individual in
order to determine plasma or whole blood levels of the blocking/dis-
placement agent at a given time point [3,4]. Also, this approach has
been extensively and directly applied to PET TO studies in large animals
[5,6]. Unfortunately, individual PK/PD analysis of drugs used in PET
TO studies of small animals, specifically, rodents, is less standard [7,8]
and at best the impact of using population-based assessments in rodents
is poorly described. Accurate quantification of PK/PD on an individual
basis is rationally justified because technical errors during drug ad-
ministration (e.g. faulty injection or partial volume injected), as well as
individual variability in metabolism (e.g. due to either genetic or en-
vironmental factors [9]) cannot be adequately corrected if a population
average PK/PD curve is used. Overcoming this bias would benefit
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accuracy of the preclinical PET TO image quantification and would
facilitate confident selection of novel radiotracers and drugs suitable for
further translational research.
Foreseeably, the main limiting factors for implementing individual
PK/PD analysis as standard practice in small animal PET studies are: (1)
the extremely low levels of blocking or displacement agents con-
centration in the whole blood/plasma which might represent challenges
in terms of detection limits of chromatographic instrumentation, such
as high performance liquid chromatography (HPLC); and (2) most cri-
tically, the small blood sampling volume allowed for small animals
[10]. Here we propose a rapid and practical analytical HPLC method
which allows for detection of blood and tissue concentrations of a well-
known selective 18 kDa translocator protein (TSPO) drug, PK11195 (1-
[2-chlorophenyl]-N-[1-methyl-propyl]-3-isoquinoline carboxamide), in
small (sub-mililitre) volumes of rat whole blood and tissue samples.
Whole blood analysis was preferred over plasma analysis, as PK11195 is
known to bind to erythrocytes and plasma proteins [11,12].
2. Materials and methods
2.1. Reagents and solvents
PK11195 (> 99% purity) was purchased from Abcam (Cambridge,
UK). The gradient grade HiperSolv CHROMANORM® acetonitrile
(> 99.9% purity) was acquired from VWR Chemicals (Lutterworth,
UK). The ultrapure water was obtained by using Millipore Smart2Pure
water purification system. Prior to use, both acetonitrile and water
were filtered through 0.22 μm Magna nylon membranes (GVS, USA)
using a chemical duty vacuum pump (Millipore, US). DMSO was pur-
chased from Fisher Bioreagents (US).
2.2. Animals and sample collection
All experiments were authorized by the local University of
Edinburgh animal welfare and ethical review committee and were
conducted in accordance with the Home Office Animals (Scientific
Procedures) Act 1986. Healthy naïve adult male Sprague-Dawley rats
(373 ± 20 g, mean ± SD, n=6) were anaesthetised using 2.0–2.5%
isoflurane (50/50 oxygen/nitrous oxide, 1 L/min). The femoral artery
was cannulated for blood collection post drug administration as de-
scribed previously [13] and PK11195 (5mg/kg in 100% DMSO, 100 μL)
was injected via tail vein (bolus i.v.). Animals have been divided into
two groups: animals 1, 2 and 3 had their arterial blood samples taken at
0.5, 1, 2 and 3min post-PK11195 injection; whereas animals 4, 5 and 6
had their arterial blood samples taken at 5, 15, 30 and 60min post-
PK11195 injection. In total, 4 mL of blood have been collected into
heparinized tubes (50 IU/mL) from each animal, i.e. 1 mL per time
point, in order to respect the blood volume collection limits for rats
[10]. Immediately after, each 1mL sample was sub-aliquot into 300 μL
samples for subsequent HPLC analysis. The tissue samples, including
heart, lungs, brain and spleen were collected at a terminal point, i.e.
3 min (animals 1, 2, 3) and 60min (animals 4, 5, 6) post-PK11195 in-
jection. Following collection, both whole blood and tissue samples were
frozen on dry ice and stored at −80 °C until processed. Analysis of
whole-blood samples rather than plasma processed samples is common
place to drugs that bind to blood cells [14,15].
2.3. Analytical HPLC method development
2.3.1. HPLC system and PK11195 detection
HPLC analysis was performed on a Dionex Ultimate 3000 UHPLC
(Thermo Scientific, UK). The chromatographic separation was carried
out at 25 °C using a Luna® C18(2) 150mm×4.6mm, 10 μm column
(Phenomenex, UK). The mobile phase consisted of 70% acetonitrile in
water. A reference standard PK11195 sample has been prepared at
1mg/mL concentration in acetonitrile:water (70:30). A 100 μL sample
of the PK11195 reference standard was injected and the column was
eluted with an isocratic mobile phase (1mL/min flow for 10min). The
peak of PK11195 in the samples was detected by UV/Vis detector at
331 nm.
2.3.2. Chromatographic method validation
In order to test the validity of the analytical HPLC method, the HPLC
method repeatability and intermediate precision, linearity, limit of
detection (LOD) and limit of quantitation (LOQ) were calculated.
In order to determine the linearity of the method, the calibration
curve of PK11195 was generated by injecting freshly prepared PK11195
dissolved in acetonitrile:water (70:30) (concentration range
7.5–1000 ng/mL, n=3 per concentration) using the analytical HPLC
method described in Section 2.3.1. The concentration was plotted
versus the average peak area. The two lowest concentrations at which
the PK11195 peak could be visually identified (7.5 and 25 ng/mL) and
two concentrations in between (10 and 15 ng/mL) were selected for
analysis of system repeatability and injected onto the HPLC system 6
consecutive times using the same conditions. The experiment was re-
peated on another day for intermediate precision testing. Measuring
system repeatability and intermediate precision at concentrations
around the LOD/LOQ values provides additional confidence on the
robustness of the obtained measures, as the analysis of the samples
around these working limits are more challenging and represent worst-
case conservative scenario. Both repeatability and intermediate preci-
sion were expressed as percentage relative standard deviation (%RSD).
The LOD and LOQ for the proposed HPLC method were calculated as
previously described [16] and using the formulae:
= ×LOD 3.3
S (1)
= ×LOQ 10
S (2)
where, σ is the standard deviation of the y-intercept, and S is the slope
of the calibration curve. Additionally, LOD was determined by calcu-
lating signal to noise ratio and peak detectability was defined as a S/N
ratio> 2, according to the International Council for Harmonisation
(ICH) standards [17].
2.4. PK11195 PK/PD measurements in rat blood and tissue
2.4.1. Blood and tissue sample preparation and HPLC analysis
On the day of the HPLC experiment, ultrapure water was added to
the defrosted tissue samples (heart, lungs and spleen 1:1, w/v; and
brain 1:3, w/v) in order to facilitate homogenization. The homogenized
tissues and arterial blood samples were centrifuged at 2000 rpm 4 °C
(24 position rotor, Heraeus Megafuge 8R, Thermo Scientific) for 5min.
The whole blood and tissue supernatants were collected and cen-
trifugation was repeated 3 times under the same conditions in order to
recover as much whole blood and tissue supernatant as possible.
Freezing-thawing cycle of the whole blood sample causes cell lysis,
therefore the resultant supernatant represents the whole blood drug
content, in line with previously described blood sample collection and
storage/processing methods [18,19]. The cell-free tissue and whole
blood and tissue supernatants were denatured using acetonitrile (1:1.4,
v/v) and centrifuged at 2000 rpm 4 °C for 4min. Following protein
precipitation, the final supernatants were collected for HPLC analysis.
The prepared samples were analysed using the method described in
Section 2.3.1. The measured PK11195 peak area was converted to
concentration by applying linear regression equation obtained from the
calibration curve.
2.4.2. Comparison of calculated versus measured PK11195 concentration
in rat whole blood
It was important to assess how accurate the calculated PK11195
concentrations were relative to measured PK11195 concentration using
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the HPLC method described in this study. The results obtained from the
analysed blood samples collected at 0.5, 1, 2, 3, 5, 15, 30 and 60min
after the administration of PK11195 were compared to the concentra-
tion of PK11195 estimated from the two-phase exponential regression
equation (Eq. 3) derived from the population-based blood PK/PD curve.
2.5. Statistical analysis and PK/PD data fitting
Statistical analysis of the results was performed using GraphPad
Prism 5 (GraphPad Software, USA). Statistical significance was esti-
mated by one-way ANOVA followed by Bonferroni or Dunnett's post-
hoc tests. One-phase decay exponential regression model was applied to
determine PK/PD of PK11195 in individual animals, and two-phase
decay exponential regression model was applied in order to estimate
the population pharmacokinetic whole blood profile of PK11195.
3. Results
3.1. Analytical HPLC method development
The average PK11195 retention time (tR) was 5.18 ± 0.04min
(mean ± SD, n=80 different injections used for method development,
Fig. 1A). Collected data showed the HPLC signal measured with the
developed method was linear relative to the sample concentration
(r2=0.999, Fig. 1B) and the fitting residuals were ± 0.005 mAU·min
(Fig. 1C) with only two outliers outside the 95% confidence interval
correspondent to concentrations 100 ng/mL and 500 ng/mL. The mea-
sured method repeatability on day 1 and 2 was 11.3% and 9.5% on
average, respectively. The mean value for the intermediate precision
was 17.3% (Table 1).
The calculated LOD for the present analytical HPLC method was
11.7 ng/mL, and LOQ was equal to 35.4 ng/mL when determined using
standard equations (Eq. 1 and 2). The S/N ratio analysis showed this
ratio was higher than 2 for all the PK11195 concentrations tested:
2.4 ± 0.6 for 7.5 ng/mL, 3.0 ± 0.5 for 10 ng/mL, 3.1 ± 0.4 for
15 ng/mL and 4.5 ± 0.5 for 25 ng/mL (mean ± SD, n=12).
3.2. PK11195 PK/PD measurements in rat blood and tissue
In order to test the feasibility and reproducibility of the proposed
analytical HPLC method with sub-millilitre injection volumes of bio-
logical samples containing PK11195, upon collection, each 1mL whole
blood sample was divided into three equal volumes (i.e. 3 x ~300 μL),
frozen for storage, then defrosted, centrifuged and denatured to obtain
supernatant and analysed using HPLC. Each one out of three 300 μL
whole blood samples was processed and analysed on a different day
during the course of three days. On average, the inter-sample variability
was 15.5% (Table 2), in line with inter-day variability assessed using
reference standard solutions of PK11195. The retention time of
PK11195 in whole blood and tissue samples remained consistent
throughout the study (5.18 ± 0.03min, n=94) and it was identical to
the retention time of the reference standard.
Fig. 2 presents the PK/PD response of PK11195 in rat whole blood
over time. Measured half-life (T1/2) for animal 1, 2 and 3 were 0.6min,
0.2 min and 0.8min, respectively. Area under the curve (AUC) for an-
imals 1, 2 and 3 were 1790, 980.8 and 886.1 ng/mL·min, respectively
(Fig. 2A). Measured T1/2 for animals 4, 5 and 6 were 15.9min, 11.9 min
and 12.2min, respectively. Area under the curve (AUC) for animals 4, 5
and 6 were 2989, 9516 and 5709 ng/mL·min, respectively (Fig. 2B). By
combining the data obtained from all individual animals in the study
and by applying two-phase exponential regression model to this data
set, a population average curve was obtained (Fig. 2C) and an equation
was derived, which can be used to determine PK11195 concentration in
rat whole blood at any given time point:= + × + ×PK e e[ 11195] 7.8 523.2 222.4time time0.4 0.03 (3)
The calculated PK11195 concentration from the population average
curve was compared with the measured PK11195 concentration in rat
whole blood at 0.5, 1, 2, 3, 5, 15, 30 and 60min post-injection (Fig. 3).
The results showed that the PK11195 concentration obtained using Eq.
3 was significantly different from measured PK11195 concentration in
at least one animal at every time point, with the exception of samples
collected at 60min post-injection, (one-way ANOVA followed by Dun-
netts' multiple comparison test, p < 0.05).
Fig. 1. Linearity of the proposed analytical HPLC method. A) Representative chromatogram of PK11195 1000 ng/mL (tR=5.19min). B) Calibration curve of
PK11195 (concentration range 7.5–1000 ng/mL; n=3 per concentration,± 95% CI shown as data points error bars). Linear equation: Y= 0.0006×+0.0073,
where Y= response (mAU·min), x=PK11195 concentration (ng/mL), r2=0.999. C) Residuals plot of the calibration curve and 95% CI shown as dashed lines.
CI= confidence interval.
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The developed HPLC method was also applied to investigate con-
centration of PK11195 in tissue. The PK/PD analysis showed that
PK11195 was actively and rapidly cleared from the blood and
kinetically transferred into the organs (Fig. 4). The average PK11195
concentration was not significantly different at 3min post-injection
across all the organs tested in the study (Fig. 3A), however 1 h post-
Table 1
Measured HPLC peak area for different PK11195 concentrations, repeatability and reproducibility of the developed analytical method. All data shown as average
response± SD (n=6), D1= the 1st day of sample analysis and D2= the 2nd day of sample analysis.
Concentration of PK11195
7.5 ng/mL 10 ng/mL 15 ng/mL 25 ng/mL
Average response D1 (mAU·min) 0.010 ± 0.002 0.011 ± 0.001 0.012 ± 0.002 0.020 ± 0.003
Repeatability D1 (%) 22 11 7 5
Average response D2 (mAU·min) 0.009 ± 0.001 0.010 ± 0.001 0.013 ± 0.001 0.023 ± 0.001
Repeatability D2 (%) 14 13 5 6
Intermediate precision D1 vs. D2 (%) 24 13 15 17
Table 2
Inter-sample PK/PD variability of PK11195 in biological samples. Average PK11195 whole blood concentration ± SD at different time points post-PK11195 in-
jection for individual animals (n=2 for 5min whole blood samples from animals 5 and 6, and n=3 for all remaining time points per animal) were measured using
the proposed analytical HPLC method. The level of significance in the sample group (i.e. PK11195 concentration at particular time point across three animals) was
determined using one-way ANOVA followed by Bonferroni's post hoc test (p < 0.05).
Time, min PK11195 (ng/mL) RSD, % PK11195 (ng/mL) RSD, % PK11195 (ng/mL) RSD, % p value
Animal 1 Animal 2 Animal 3
0.5 895 ± 47 5.3 702 ± 135 19.2 467 ± 29 6.1 0.0067
1 762 ± 49 6.5 388 ± 70 18 395 ± 39 9.8 0.0007
2 682 ± 64 9.3 357 ± 50 13.8 327 ± 36 11.1 0.0008
3 627 ± 42 6.7 313 ± 23 7.3 292 ± 5 1.7 < 0.0001
Animal 4 Animal 5 Animal 6
5 93 ± 47 50.4 488;415 – 240; 215 – 0.0034
15 73 ± 33 45.4 259 ± 19 7.3 138 ± 7 5.4 0.0005
30 48 ± 3 5.9 144 ± 16 11.1 94 ± 7 7.6 0.0003
60 35 ± 24 69.6 52 ± 10 18.5 48 ± 11 22.6 0.5791
Fig. 2. Individual and population-based PK/PD curves of PK11195 in rat whole blood. A) One-phase exponential regression plot representing the concentration of
PK11195 in the whole blood at 0.5, 1, 2, 3min post-intravenous administration of the animals 1, 2, 3 and B) 5, 15, 30 and 60min post-injection of the animals 4, 5, 6
(mean ± SD, n=3 per time point). C) Measured whole blood PK11195 concentrations at 0.5, 1, 2, 3, 5, 15, 30 and 60min post-injection in the animals 1 to 6,
represented by black dots and error bars (mean ± SD, n= 3 per time point), and population-based two-phase exponential regression plot (red dotted line) re-
presenting the calculated concentration of PK11195 in the whole blood over time. This regression plot was used to derive Eq. 3.
Statistically significant differences were determined using ANOVA, Bonferroni Post-hoc test, p < 0.05(*), p < 0.01(**). (For interpretation of the references to
colour in this figure legend, the reader is referred to the web version of this article.)
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injection the drug levels in the brain were significantly lower when
compared to the heart, lungs and spleen as well as lower in the spleen
when compared to the lungs (p=0.0003; one-way ANOVA, Bonferroni
multiple comparison test).
4. Discussion
In this study, an analytical HPLC method was developed for the
detection of nanomolar concentrations of the TSPO selective drug,
PK11195, in small size biological samples. The developed method has
shown to be feasible, reproducible and linear. Robustness of the method
was successfully challenged with nanomolar concentrations and sub-
millilitre volumes. Results presented here highlight and quantify the
bias associated with population-based PK/PD analysis versus individual
analysis of small animal data, with consequent impact on drug studies,
namely PET TO data quantification. Even though the described HPLC
Fig. 3. Comparison of calculated versus measured concentration of PK11195 in whole blood. Calculated vs measured PK11195 concentration in rodent whole blood
at 0.5min (A), 1 min (B), 2 min (C), and 3min (D) post-injection of PK11195 (mean ± SD, n=3, one-way ANOVA followed by Dunnetts' multiple comparison test
(p < 0.05)). Calculated vs measured PK11195 concentration in rodent blood at 5 min (E), 15min (F), 30min (G), and 60min (H) post-injection of PK11195
(mean ± SD, n=3, one-way ANOVA followed by Dunnetts' multiple comparison test (p < 0.05)). p < 0.05(*), p < 0.01(**), p < 0.001(***).
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method is valid only for PK11195, upon developing appropriate HPLC
methods, the same approach could be potentially applied for testing
PK/PD of different drugs.
The proposed analytical HPLC method for PK11195 detection
proved to be feasible using both chemical and biological samples
(whole blood and tissue). On average, the method repeatability was
17.3% for chemical PK11195 dilutions and 13.5% for whole blood
samples containing tracer amounts of PK11195. A 5 to 15% repeat-
ability limit in chromatographic measurements has been defined for
analysis at trace levels [20], and even though the average intermediate
precision among PK11195 measurements in chemical samples was
higher than this limit, the value for PK11195 detection in blood samples
was within the required range (Tables 1 and 2). Other validation cri-
teria were met as the method showed exceptionally good linearity even
at LOD, which was at nanomolar range. Our results are in line with
previously published data indicating that, in chromatographic analysis,
smaller values of the detection limit and the quantification limit were
better described by visual analysis or S/N ratio, albeit larger variations
[21]. Furthermore, we have quantified the S/N ratio for the peaks ob-
served in the HPLC trace at the four lowest concentrations, as an ad-
ditional line of evidence to test the sensitivity of the method. That
analysis has shown the LOD was 7.5 ng/mL with a S/N ratio of
2.4 ± 0.6 (mean ± SD, n=12). Taken together, all this criteria pin-
point the developed HPLC method as a reproducible and sensitive
analytical tool for PK11195 levels above 7.5 ng/mL.
Previously described methods for HPLC analysis of PK11195 were
overall similar to the method proposed in this study, but there was a
large range of HPLC mobile phases and UV wavelengths used for
PK11195 elution and detection. The UV light wavelengths ranged from
254 nm to 310 nm, and organic solvent:water ratio of the mobile phase
ranged between 30:70 to 80:20 [22–24]. Using our chromatographic
system, and after testing a wide range of UV wavelengths, we concluded
that the optimal wavelength to detect PK11195 in biological samples
was 331 nm (data not shown). In 2008, Wala et al. [25] has also de-
scribed a HPLC method of PK11195 detection and PK/PD analysis in
rats. They have reported PK11195 detection at 240 nm UV channel
using K₂HPO₄:methanol:acetonitrile (35:63:2) as mobile phase and
Supelco LC-8 column with a retention time twice as long as the one
obtained with our method (tR=10min versus tR=5.18min). Even
though %RSD for repeatability and reproducibility at 500 ng/mL
PK11195 were 7.7% and 7.9%, respectively, it is worth noting that the
concentration used by the authors was 50–65 fold higher than the
concentrations used for repeatability and intermediate precision testing
using our method, hence more favourable %RSD values. Despite these
differences, the LOD was 10 ng/mL. Therefore, the results reported in
the current study are comparable with the findings of Wala et al. in
spite of the different methods used for blood processing. This is likely
due to the known reversible PK11195 binding to erythrocytes and
plasma proteins – albumin and α1-acid glycoprotein [11,12]. As the
PK11195 in plasma binds to tissues, the erythrocyte-bound and plasma
protein-bound PK11195 may dissociate, causing fluctuations in plasma
PK11195 levels. As a result, equilibrium between free and bound
PK11195 levels is never reached. This justifies the use of whole blood
drug for the HPLC analysis, as ultimately PK11195 present in whole
blood contributes to the extent of its effects. Furthermore, other pre-
viously reported HPLC studies of drugs that are known to bind to the
red blood cells have also used whole blood measurements and reported
a blood collection and storage method similar the one described in this
manuscript [18,19].
Most importantly, we were also able to demonstrate that the usage
of population average PK/PD data of PK11195 for rodent PET TO image
quantification can result in notable quantitative bias (0.3 to 1.7 fold
difference between calculated and measured PK11195 whole blood
levels). The larger inter-individual variability is likely to be a result of
operational artefacts and individual variability in metabolism in dif-
ferent animals. Still, this issue can be overcome by applying the pro-
posed analytical HPLC method as standard PK/PD determination test,
in order to improve the accuracy of the preclinical PET TO data
quantification and accelerate confident translation of novel radiotracers
and drugs from the preclinical to clinical research. PET TO small animal
studies play an important role in the early phase drug development, as
they assist dosing regimen optimisation for subsequent clinical trials
[26–28]. Therefore, the adherence to individual-based PK/PD analysis,
such as the one reported here, would significantly improve the accuracy
of preclinical PET TO quantification, and consequently supports the
translational process.
Even though there are other slightly more sensitive chromato-
graphic systems for PK11195 detection available, such as LC/MS
[29–31], our proposed method proved to be relatively inexpensive,
rapid and reliable. The adherence to this individual approach could be
rapidly realised across laboratories. Another advantage of the devel-
oped method is that the small blood sample size of approximately
300 μL is sufficient for the robust analysis. It offers the opportunity for
reliable quantitative PK/PD analysis of PK11195 in smaller species.
In addition to whole blood data, in this study we have also demon-
strated that it is possible to detect PK11195 in rodent tissues, such as heart,
lungs, brain and spleen, using the proposed sample processing and ana-
lytical HPLC methods. The data becomes extremely useful when de-
termining a direct relationship between blocking drug concentration and
percentage occupancy in the target tissue during preclinical PET radio-
tracer development process and early preclinical phases of drug discovery.
Even though in the clinical drug development environment there is no
readily available access to tissue [32], given the ability of the proposed
HPLC method to perform well even with small quantities (sub-millilitre)
blood samples, this approach could potentially be applied for small human
tissue samples obtained during tissue biopsy procedures.
Fig. 4. Concentration of PK11195 in the different tissues. The concentration of PK11195 across different organs at A) 3min and B) 60min post-injection. Results
presented as mean ± SD, n=3. Statistically significant differences were determined using one-way ANOVA followed by Bonferroni multiple comparison test,
p < 0.05(*), p < 0.01(**), p < 0.001(***).
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5. Conclusions
A robust chromatographic method to measure PK11195 con-
centration in small volume rodent whole blood samples and tissue was
developed. This method uses sub-millilitre sample volumes to rapidly
and reproducibly assess PK/PD of PK11195 in small animals. Data
collected highlighted the need for individually measured PK/PD drug
concentration levels in samples, in order to derive more accurate drug
exposure levels compared with population-based estimates often used
in preclinical research with small animals. Even though different HPLC
methods would have to be developed for different drugs, this proof-of-
concept study using PK11195 suggests that the proposed methodolo-
gical approach is feasible even with sub-millilitre volumes and, if ap-
plied more widely, has potential to help eliminate the bias in small
animal TO PET data quantification.
Acknowledgements
We would like to thank all the members of preclinical PET group at
the University of Edinburgh for their assistance during this study.
Funding
The British Heart Foundation supported the purchase of equipment
[BHF RE/13/3/20183 and RG/16/10/32375] and consumables [BHF
PG/17/83/33370] used in this work. AS, TW and AT are supported by
the British Heart Foundation [BHF RE/13/3/20183 and RG/16/10/
32375]. CA and CL are funded by Edinburgh Preclinical Imaging and
Edinburgh Imaging Facilities, respectively.
Declaration of interest
None.
References
[1] M.E. Phelps, Positron emission tomography provides molecular imaging of biolo-
gical processes, Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 9226–9233, https://doi.
org/10.1073/pnas.97.16.9226.
[2] G.C. Van De Bittner, E.L. Ricq, J.M. Hooker, A philosophy for CNS radiotracer
design, Acc. Chem. Res. 47 (2014) 3127–3134, https://doi.org/10.1021/
ar500233s.
[3] S. Zamuner, E.A. Rabiner, S.A. Fernandes, M. Bani, R.N. Gunn, R. Gomeni, E. Ratti,
V.J. Cunningham, A pharmacokinetic PET study of NK1 receptor occupancy, Eur. J.
Nucl. Med. Mol. Imaging 39 (2012) 226–235, https://doi.org/10.1007/s00259-
011-1954-2.
[4] F. Vandenhende, D. Renard, Y. Nie, A. Kumar, J. Miller, J. Tauscher, J. Witcher,
Y. Zhou, D.F. Wong, Bayesian hierarchical modeling of receptor occupancy in PET
trials, J. Biopharm. Stat. 18 (2008) 256–272, https://doi.org/10.1080/
10543400701697158.
[5] S. Hjorth, C. Karlsson, A. Jucaite, K. Varnäs, U. Wählby Hamrén, P. Johnström,
B. Gulyás, S.R. Donohue, V.W. Pike, C. Halldin, L. Farde, A PET study comparing
receptor occupancy by five selective cannabinoid 1 receptor antagonists in non-
human primates, Neuropharmacology 101 (2016) 519–530, https://doi.org/10.
1016/j.neuropharm.2015.03.002.
[6] K. Varnas, A. Jureus, P. Johnstrom, C. Ahlgren, P. Schott, M. Schou, S. Gruber,
E. Jerning, J. Malmborg, C. Halldin, L. Afzelius, L. Farde, Integrated strategy for use
of positron emission tomography in nonhuman primates to confirm multitarget
occupancy of novel psychotropic drugs: an example with AZD3676, J. Pharmacol.
Exp. Ther. 358 (2016) 464–471, https://doi.org/10.1124/jpet.116.234146.
[7] Y. Nakatani, M. Suzuki, M. Tokunaga, J. Maeda, M. Sakai, H. Ishihara,
T. Yoshinaga, O. Takenaka, M.R. Zhang, T. Suhara, M. Higuchi, A small-animal
pharmacokinetic/pharmacodynamic PET study of central serotonin 1A receptor
occupancy by a potential therapeutic agent for overactive bladder, PLoS One 8
(2013) 1–13, https://doi.org/10.1371/journal.pone.0075040.
[8] A. Parente, P.K. Feltes, D. Vallez Garcia, J.W.A. Sijbesma, C.M. Moriguchi Jeckel,
R.A.J.O. Dierckx, E.F.J. de Vries, J. Doorduin, Pharmacokinetic analysis of 11C-
PBR28 in the rat model of herpes encephalitis: comparison with (R)-11C-PK11195,
J. Nucl. Med. 57 (2016) 785–791, https://doi.org/10.2967/jnumed.115.165019.
[9] P. Daublain, K.I. Feng, M.D. Altman, I. Martin, S. Mukherjee, R. Nofsinger,
A.B. Northrup, R. Tschirret-Guth, M. Cartwright, C. McGregor, Analyzing the po-
tential root causes of variability of pharmacokinetics in preclinical species, Mol.
Pharm. 14 (2017) 1634–1645, https://doi.org/10.1021/acs.molpharmaceut.
6b01118.
[10] K.H. Diehl, R. Hull, D. Morton, R. Pfister, Y. Rabemampianina, D. Smith, J.M. Vidal,
C. Van De Vorstenbosch, A good practice guide to the administration of substances
and removal of blood, including routes and volumes, J. Appl. Toxicol. 21 (2001)
15–23, https://doi.org/10.1002/jat.727.
[11] J.M.M. Olson, B.J. Ciliax, W.R. Mancini, A.B. Young, Presence of peripheral-type
benzodiazepine binding sites on human erythrocyte membranes, Eur. J. Pharmacol.
152 (1988) 47–53.
[12] A. Lockhart, B. Davis, J.C. Matthews, H. Rahmoune, G. Hong, A. Gee, D. Earnshaw,
J. Brown, The peripheral benzodiazepine receptor ligand PK11195 binds with high
affinity to the acute phase reactant α1-acid glycoprotein: implications for the use of
the ligand as a CNS inflammatory marker, Nucl. Med. Biol. 30 (2003) 199–206,
https://doi.org/10.1016/S0969-8051(02)00410-9.
[13] G. Warnock, M.A. Bahri, D. Goblet, F. Giacomelli, C. Lemaire, J. Aerts, A. Seret,
X. Langlois, A. Luxen, A. Plenevaux, Use of a beta microprobe system to measure
arterial input function in PET via an arteriovenous shunt in rats, EJNMMI Res. 1
(2011) 1–11, https://doi.org/10.1186/2191-219X-1-13.
[14] B. Blomback, M. Blomback, P. Edman, B. Hessel, Mechanism of Haemolysis Caused
by Freezing and its Prevention, vol. 193, (1962), pp. 884–885.
[15] J.E. Lovelock, The haemolysis of human red blood cells by freezing and thawing,
Biochem. Biophys. Acta. 10 (1953) 414–426.
[16] A.D. Chonkar, R.S. Managuli, J.V. Rao, N. Udupa, Development and validation of
reversed phase high-performance liquid chromatography method for estimation of
lercanidipine HCl in pure form and from nanosuspension formulation, J. Basic Clin.
Pharm. 7 (2015) 17–22, https://doi.org/10.4103/0976-0105.170586.
[17] A. Shrivastava, V. Gupta, Methods for the determination of limit of detection and
limit of quantitation of the analytical methods, Chronicles Young Sci 2 (2011) 21,
https://doi.org/10.4103/2229-5186.79345.
[18] X. Gao, J. Chen, N. Mei, W. Tao, W. Jiang, X. Jiang, HPLC determination and
pharmacokinetic study of indapamide in human whole blood, Chromatographia 61
(2005) 581–585, https://doi.org/10.1365/s10337-005-0548-1.
[19] C.A. Griffith, L.J. Owen, R. Body, G. Mcdowell, B.G. Keevil, Development of a
method to measure plasma and whole blood choline by liquid chromatography
tandem mass spectrometry, Ann. Clin. Biochem. 47 (2010) 56–61, https://doi.org/
10.1258/acb.2009.008191.
[20] A. Bose, HPLC calibration process parameters in terms of system suitability test,
Austin Chromatogr 1 (2014) 1–4, https://doi.org/10.1080/01483919108049375.
[21] M. Ribani, C.H. Collins, C.B.G. Bottoli, Validation of chromatographic methods:
evaluation of detection and quantification limits in the determination of impurities
in omeprazole, J. Chromatogr. A 1156 (2007) 201–205, https://doi.org/10.1016/j.
chroma.2006.12.080.
[22] A. Jučaite, Z. Cselényi, A. Arvidsson, G. Åhlberg, P. Julin, K. Varnäs, P. Stenkrona,
J. Andersson, C. Halldin, L. Farde, Kinetic analysis and test-retest variability of the
radioligand [11C](R)-PK11195 binding to TSPO in the human brain - a PET study in
control subjects, EJNMMI Res. 2 (2012) 1–13, https://doi.org/10.1186/2191-219X-
2-15.
[23] J. Yankam Njiwa, N. Costes, C. Bouillot, S. Bouvard, S. Fieux, G. Becker,
E. Levigoureux, G. Kocevar, C. Stamile, J.B. Langlois, R. Bolbos, C. Bonnet, L. Bezin,
L. Zimmer, A. Hammers, Quantitative longitudinal imaging of activated microglia
as a marker of inflammation in the pilocarpine rat model of epilepsy using [11C]-
(R)-PK11195 PET and MRI, J. Cereb. Blood Flow Metab. 37 (2017) 1251–1263,
https://doi.org/10.1177/0271678X16653615.
[24] F. Pugliese, O. Gaemperli, A.R. Kinderlerer, F. Lamare, J. Shalhoub, A.H. Davies,
O.E. Rimoldi, J.C. Mason, P.G. Camici, Imaging of vascular inflammation with
[11C]-PK11195 and positron emission tomography/computed tomography angio-
graphy, J. Am. Coll. Cardiol. 56 (2010) 653–661, https://doi.org/10.1016/j.jacc.
2010.02.063.
[25] E.P. Wala, J.W. Sloan, X. Jing, Pharmacokinetics of the peripheral benzodiazepine
receptor antagonist, PK 11195, in rats. The effect of dose and gender, Pharmacol.
Res. 41 (2000) 461–468, https://doi.org/10.1006/phrs.1999.0617.
[26] S. Abanades, J. Van Der Aart, J.A.R. Barletta, C. Marzano, G.E. Searle, C.A. Salinas,
J.J. Ahmad, R.R. Reiley, S. Pampols-Maso, S. Zamuner, V.J. Cunningham,
E.A. Rabiner, M.A. Laruelle, R.N. Gunn, Prediction of repeat-dose occupancy from
single-dose data: characterisation of the relationship between plasma pharmaco-
kinetics and brain target occupancy, J. Cereb. Blood Flow Metab. 31 (2011)
944–952, https://doi.org/10.1038/jcbfm.2010.175.
[27] K.S. Lim, J.S. Kwon, I.J. Jang, J.M. Jeong, J.S. Lee, H.W. Kim, W.J. Kang, J.R. Kim,
J.Y. Cho, E. Kim, S.Y. Yoo, S.G. Shin, K.S. Yu, Modeling of brain D2 receptor oc-
cupancy-plasma concentration relationships with a novel antipsychotic, YKP1358,
using serial PET scans in healthy volunteers, Clin. Pharmacol. Ther. 81 (2007)
252–258, https://doi.org/10.1038/sj.clpt.6100049.
[28] S. Patel, R. Gibson, In vivo site-directed radiotracers: a mini-review, Nucl. Med.
Biol. 35 (2008) 805–815, https://doi.org/10.1016/j.nucmedbio.2008.10.002.
[29] M. Fani, X. Wang, G. Nicolas, C. Medina, I. Raynal, M. Port, H.R. Maecke,
Development of new folate-based PET radiotracers: preclinical evaluation of68Ga-
DOTA-folate conjugates, Eur. J. Nucl. Med. Mol. Imaging 38 (2011) 108–119,
https://doi.org/10.1007/s00259-010-1597-8.
[30] B. Mackowiak, L. Li, M.A. Welch, D. Li, J.W. Jones, S. Heyward, M.A. Kane,
P.W. Swaan, H. Wang, Molecular basis of metabolism-mediated conversion of
PK11195 from an antagonist to an agonist of the constitutive androstane receptor s,
Mol. Pharmacol. Mol Pharmacol. 92 (2017) 75–87, https://doi.org/10.1124/mol.
117.108621.
[31] S. Eberl, A. Katsifis, M.A. Peyronneau, L. Wen, D. Henderson, C. Loc'h, I. Greguric,
J. Verschuer, T. Pham, P. Lam, F. Mattner, A. Mohamed, M.J. Fulham, Preclinical in
vivo and in vitro comparison of the translocator protein PET ligands [18F]PBR102
and [18F]PBR111, Eur. J. Nucl. Med. Mol. Imaging 44 (2017) 296–307, https://doi.
org/10.1007/s00259-016-3517-z.
[32] R.J. Hargreaves, E.A. Rabiner, Translational PET imaging research, Neurobiol. Dis.
61 (2014) 32–38, https://doi.org/10.1016/j.nbd.2013.08.017.
A. Stadulytė, et al. Journal of Chromatography B 1118–1119 (2019) 33–39
39
